Tag: common

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

LOS ANGELES, July 08, 2025 (GLOBE NEWSWIRE) -- Capital World Investors (“CWI”) announces that on July 8, 2025 it acquired an aggregate of 338,554 common shares (the “Purchased Shares”) of MEG Energy Corp. (“MEG”) through the facilities of the Toronto Stock Exchange. Immediately following the acquisition of the Purchased Shares, CWI had control or direction over an aggregate of 22,281,631 common shares of MEG representing 8.75% of the 254,378,035 MEG common shares then outstanding.

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

Clean-Label Botanical Formula Aligns with 2025 Demand for the Best Natural Ingredients in Blood Sugar and Glucose Balance SupportSan Francisco

As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox.

Transition Accompanies Strong Revenue Growth, Expanded Profitability, and Strengthened Balance Sheet

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016^® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.